Randy Scott

Partner, Co-Founder

2012 - Current

HealthQuest Capital invests in innovative and market-ready companies in health care that improve value for patients, providers and payers.

Board of Directors, Chair

2021

At 83bar, we shorten the patient journey from years to minutes using our Patient Activation Platform to Locate, Educate & Navigate patients for Commercial, Clinical Trial, Device, Diagnostic & Pharma clients. We bridge the gap between patient awareness and patient action to drive positive healthcare outcomes.

Board of Directors

2021

Thirty Madison is the human-first health company bringing specialized care and treatment to everyone. Parent company of Keeps, Cove, Evens, and Picnic.

Board Of Directors, Chair

2018

The nation’s leading employer-facing health intelligence software. Today, over 4,000 employers use Springbuk’s software to glean actionable insights to improve their population’s health.

Board Of Directors

2016

Magnolia's SteriPath device nearly eliminates false positive blood cultures and with it hundreds of millions of dollars of unnecessary medical care.

Board of Directors

2023

Board Of Directors

2015 - 2023

Trice is revolutionizing orthopedic extremity surgery by allowing procedures formerly done in the OR to move to procedure rooms and doctors offices. Products include MiEye optical needle, SegWay endoscopic carpal tunnel release, and Tenex treatments for chronic tendonitis and diabetic foot ulcer.

Board of Directors

2015 - 2018

Virmedica simplifies the process for a patient to gain access to specialty pharmaceuticals by automating benefits verification and pre-authorization. Acquired by CareMetx.

Board Of Directors

2016 - 2018

Avizia (acquired by American Well) provides end-to-end telemedicine solutions that connect any provider to any patient anywhere.

CEO

2003 - 2010

NovaMin makes a proprietary active ingredient for oral care and dental products. I led the spin-out of this company from USBiomaterials, $15MM+ of funding of the company from institutional venture capital funds and other sources, and the recent sale of the Company to GlaxoSmithKline.